GCN2 in Cancer: Molecular Mechanisms to Therapeutic Potential.

IF 2.3 4区医学 Q3 ONCOLOGY

Current cancer drug targets Pub Date : 2025-01-29 DOI:10.2174/0115680096325045241120113825

Hayley Prescott, Makhdoom Sarwar, Martin Dickens, Evelyn Sattlegger

引用次数: 0

Abstract

Virtually every mammalian cell contains the cytoplasmic protein kinase General Control Non-depressible 2 (GCN2), which allows cells to cope with stresses such as nutrient shortage. While GCN2 is not essential for normal cells, in many can-cers GCN2 assumes a pivotal role, becoming indispensable for cell growth and sur-vival. This has spurred significant interest in GCN2 as a promising target for anti-cancer therapies. In this review, we give an overview of the known links between GCN2 and cancer.

查看原文本刊更多论文

GCN2在癌症中的分子机制和治疗潜力。

几乎每个哺乳动物细胞都含有细胞质蛋白激酶一般控制非抑制性2 (GCN2)，它使细胞能够应对诸如营养短缺等压力。虽然GCN2对正常细胞来说不是必需的，但在许多癌症中，GCN2扮演着关键角色，对细胞生长和生存不可或缺。这激发了人们对GCN2作为抗癌治疗的一个有希望的靶点的极大兴趣。在这篇综述中，我们概述了已知的GCN2与癌症之间的联系。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Current cancer drug targets 医学-肿瘤学

CiteScore

5.40

自引率

0.00%

发文量

105

审稿时长

1 months

期刊介绍： Current Cancer Drug Targets aims to cover all the latest and outstanding developments on the medicinal chemistry, pharmacology, molecular biology, genomics and biochemistry of contemporary molecular drug targets involved in cancer, e.g. disease specific proteins, receptors, enzymes and genes. Current Cancer Drug Targets publishes original research articles, letters, reviews / mini-reviews, drug clinical trial studies and guest edited thematic issues written by leaders in the field covering a range of current topics on drug targets involved in cancer. As the discovery, identification, characterization and validation of novel human drug targets for anti-cancer drug discovery continues to grow; this journal has become essential reading for all pharmaceutical scientists involved in drug discovery and development.